D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-264, 2012.
DOI : 10.1038/nrc3239

M. J. Selby, Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells, Cancer Immunology Research, vol.1, issue.1, pp.32-42, 2013.
DOI : 10.1158/2326-6066.CIR-13-0013

D. F. Mcdermott and M. B. Atkins, PD-1 as a potential target in cancer therapy, Cancer Medicine, vol.16, issue.Suppl., pp.662-73, 2013.
DOI : 10.1002/cam4.106

J. D. Wolchok, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, The Lancet Oncology, vol.11, issue.2, pp.155-164, 2010.
DOI : 10.1016/S1470-2045(09)70334-1

G. Y. Ku, Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting, Cancer, vol.27, issue.22 pt 1, pp.1767-1775, 2010.
DOI : 10.1002/cncr.24951

J. Delyon, Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Annals of Oncology, vol.24, issue.6, pp.1697-703, 2013.
DOI : 10.1093/annonc/mdt027

N. D. Berman, J. W. Bristol-myers-squibb, and P. N. , Memorial Sloan- Kettering Cancer Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab, J Clin Oncol, vol.27, 2009.

S. Kelderman, Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy, vol.369, issue.2, pp.449-58, 2009.
DOI : 10.1007/s00262-014-1528-9

B. C. Carthon, Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial, Clinical Cancer Research, vol.16, issue.10, pp.2861-71, 2010.
DOI : 10.1158/1078-0432.CCR-10-0569

M. A. Postow, Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma, Journal for ImmunoTherapy of Cancer, vol.19, issue.3, p.23, 2015.
DOI : 10.1186/s40425-015-0070-4

E. Cha, Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients, Science Translational Medicine, vol.6, issue.238, pp.238-70, 2014.
DOI : 10.1126/scitranslmed.3008211

P. Kvistborg, Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Science Translational Medicine, vol.6, issue.254, pp.254-128, 2014.
DOI : 10.1126/scitranslmed.3008918

P. C. Tumeh, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.15, issue.7528, pp.568-571, 2014.
DOI : 10.1038/nature13954

J. Yuan, Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab, Proceedings of the National Academy of Sciences, vol.108, issue.40, pp.16723-16731, 2011.
DOI : 10.1073/pnas.1110814108

D. K. Sojka, Y. Huang, and D. J. Fowell, Mechanisms of regulatory T-cell suppression ??? a diverse arsenal for a moving target, Immunology, vol.178, issue.1, pp.13-22, 2008.
DOI : 10.1084/jem.20040165

P. Attia, Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti???Cytotoxic T-Lymphocyte Antigen-4, Journal of Clinical Oncology, vol.23, issue.25, pp.6043-6053, 2005.
DOI : 10.1200/JCO.2005.06.205

J. S. Weber, Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma, Journal of Immunotherapy, vol.35, issue.1, pp.89-97, 2012.
DOI : 10.1097/CJI.0b013e31823aa41c

A. Maker, Tumor regression and autoimmunity in patients treated with cytotoxic T 36

D. Hannani, Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25, Cell Research, vol.63, issue.2, pp.208-224, 2015.
DOI : 10.4161/cbt.21782

C. M. Balch, Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36
DOI : 10.1200/JCO.2009.23.4799

S. Wilgenhof, Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma, Journal of Immunotherapy, vol.36, issue.3, pp.215-237, 2013.
DOI : 10.1097/CJI.0b013e31828eed39

E. Ruffini, Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms, The Annals of Thoracic Surgery, vol.87, issue.2
DOI : 10.1016/j.athoracsur.2008.10.067

O. Hamid, A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, Journal of Translational Medicine, vol.9, issue.1, p.204, 2011.
DOI : 10.1097/CJI.0b013e31817fd8f3

F. S. Hodi, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, Proc. Natl. Acad
DOI : 10.1073/pnas.0712237105

P. A. Beavis, CD73: A potential biomarker for anti-PD-1 therapy, OncoImmunology, vol.4, issue.11, p.1046675, 2015.
DOI : 10.1158/0008-5472.CAN-14-0957

L. B. Alexandrov, Signatures of mutational processes in human cancer, Nature, vol.27, issue.7463, pp.415-436, 2013.
DOI : 10.1038/nature12477

M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, and N. Hacohen, Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity, Cell, vol.160, issue.1-2, pp.48-61, 2015.
DOI : 10.1016/j.cell.2014.12.033

A. Snyder, Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, New England Journal of Medicine, vol.371, issue.23
DOI : 10.1056/NEJMoa1406498

J. Med-allen and E. M. , doi:10.1056/NEJMoa1406498 46 Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.350, issue.80, pp.2189-2199, 2014.

N. A. Rizvi, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, issue.6230, pp.124-128, 2015.
DOI : 10.1126/science.aaa1348

D. T. Le, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2520, 2015.
DOI : 10.1056/NEJMoa1500596

E. B. Garon, Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21
DOI : 10.1056/NEJMoa1501824

C. Robert, Nivolumab in previously untreated melanoma without BRAF mutation, N

C. Robert, Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015.
DOI : 10.1056/NEJMoa1503093

M. A. Postow, Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab, Journal of Translational Medicine, vol.12, issue.Suppl 1, p.8, 2014.
DOI : 10.1056/NEJMoa1200690

R. Kefford, Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475, ASCO Annual Meeting, pp.5-2014, 2014.

A. Daud, Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001

L. Carbognin, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers, PLOS ONE, vol.348, issue.6230, p.130142, 2015.
DOI : 10.1371/journal.pone.0130142.s001

J. Larkin, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.15053111501200210-1056, 2015.
DOI : 10.1056/NEJMoa1504030

J. C. Mbongue, The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity, Vaccines, vol.3, issue.3, pp.703-732, 2015.
DOI : 10.3390/vaccines3030703

I. D. Jung, Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells, FEBS Letters, vol.17, issue.7, pp.1449-56, 2007.
DOI : 10.1016/j.febslet.2007.02.073

C. M. Robinson, P. T. Hale, and J. M. Carlin, The Role of IFN-?? and TNF-??-Responsive Regulatory Elements in the Synergistic Induction of Indoleamine Dioxygenase, Journal of Interferon & Cytokine Research, vol.25, issue.1, pp.20-30, 2005.
DOI : 10.1089/jir.2005.25.20

R. Das, Combination Therapy with Anti???CTLA-4 and Anti???PD-1 Leads to Distinct Immunologic Changes In Vivo, The Journal of Immunology, vol.194, issue.3, pp.950-959, 2014.
DOI : 10.4049/jimmunol.1401686

R. Ji, An immune-active tumor microenvironment favors clinical response to ipilimumab, Cancer Immunology, Immunotherapy, vol.313, issue.5795, pp.1019-1031, 2012.
DOI : 10.1007/s00262-011-1172-6

W. Hugo, Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, issue.1, pp.35-44, 2016.
DOI : 10.1016/j.cell.2016.02.065

J. M. Michot, Immune-related adverse events with immune checkpoint blockade: a comprehensive review, European Journal of Cancer, vol.54, pp.139-148, 2016.
DOI : 10.1016/j.ejca.2015.11.016

K. Schindler, Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab, ASCO Meet. Abstr, p.32, 2014.

M. K. Callahan, Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.29, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.2505

V. Shahabi, Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events, Journal of Translational Medicine, vol.11, issue.1, p.75, 2013.
DOI : 10.1186/1479-5876-11-75

D. Berman, Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma, Cancer Immun, vol.10, p.11, 2010.

S. G. Downey, Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade, Clinical Cancer Research, vol.13, issue.22, pp.6681-6689, 2007.
DOI : 10.1158/1078-0432.CCR-07-0187

A. Tarhini, E. Lo, and D. R. Minor, Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors, Cancer Biotherapy & Radiopharmaceuticals, vol.25, issue.6, pp.601-614, 2010.
DOI : 10.1089/cbr.2010.0865

J. Weber, Ipilimumab: controversies in its development, utility and autoimmune adverse events, Cancer Immunology, Immunotherapy, vol.31, issue.6, pp.823-853, 2009.
DOI : 10.1007/s00262-008-0653-8

P. A. Ascierto, Clinical experience with ipilimumab 3??mg/kg: real-world efficacy and safety data from an expanded access programme cohort, Journal of Translational Medicine, vol.12, issue.1, p.116, 2014.
DOI : 10.1111/nyas.12180

R. Antoni and R. C. , Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature, ASCO Annual Meeting | Abstracts | Meeting Library. Available at, pp.151652-156, 2015.